



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/910,033	07/23/2001	Bettina Bommanus	210212US0X	2456

22850 7590 11/19/2002

OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC
FOURTH FLOOR
1755 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VA 22202

EXAMINER

PAK, YONG D

ART UNIT	PAPER NUMBER
----------	--------------

1652

DATE MAILED: 11/19/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/910,033

Applicant(s)

BOMMANUS ET AL.

Examiner

Yong Pak

Art Unit

1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 23 October 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-41 is/are pending in the application.
- 4a) Of the above claim(s) 8-41 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-7 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 3.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

DETAILED ACTION

Claims 1-41 are pending.

Election/Restrictions

Applicant's election with traverse of Group I (claims 1-7) in Paper No. 12 is acknowledged. The traversal is on the ground(s) that Groups II and IV-VIII directly depend from the claims of Group I and therefore can not be separated. This is not found persuasive because Groups I and IV-VIII are independent inventions. Claims are drawn to patentably distinct products and methods.

Applicants also argue that Groups I and II and Groups IV and V are classified in the same subclass and do not require an undue burden on the examiner. This is not found persuasive because the groups were classified under the most comprehensive class. Because of the recognized divergent subject matter between the groups, an unduly extensive and burdensome search is required for Groups II, IV and V that is not required for Group I.

Applicants also argue that Group I and III should not be separated because the two groups are related as a product and a process of use of the product. The examiner disagrees. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the modified enzyme of Group I can be made by random mutagenesis or isolated from a naturally occurring mutant.

Art Unit: 1652

Notice of Possible Rejoinder: The Examiner notes that if claims 1-7 are found directed to an allowable product, then claims 12-18, which are directed to the process of making the patentable product, respectively, previously withdrawn from consideration as a result of a restriction requirement, would now be rejoined pursuant to the procedures set forth in the Official Gazette notice dated March 26, 1996 (1184 O.G. 86; see also MPEP 821.04, *In re Ochiai*, and *In re Brouwer*). Since process claims 7, 15, and 17 would be rejoined and fully examined for patentability under 37 CFR 1.104, applicants are instructed to amend said claims as deemed necessary according to rejections made against the elected claims.

The requirement is still deemed proper and is therefore made FINAL.

Claims 8-41 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 12.

Priority

Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

Art Unit: 1652

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-5 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 1-4 are drawn to mutant alcohol dehydrogenase wherein at least one acidic amino acid is modified and results in a mutant enzyme with increased affinity towards NAD(H). Therefore, these claims are drawn to a genus of alcohol dehydrogenase, with any structure and from any source. The specification only teaches one representative species, SEQ ID NO:2, from *Lactobacillus brevis*. One representative species is not enough to describe the whole genus. Although claim 5 limits the source of the enzyme to a *L. brevis*, the structure of the mutant enzyme is still unknown. Therefore, the specification fails to describe other representative species of the genus of mutant alcohol dehydrogenase.

Given this lack of description of the representative species encompassed by the genus of the claims, the specification fails to sufficiently describe the claimed invention in such full, clear, concise, and exact terms that a skilled artisan would recognize that applicants were in possession of the inventions of claim 1-5.

Claims 1-5 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the mutant alcohol dehydrogenase of SEQ ID

Art Unit: 1652

NO:2, does not reasonably provide enablement for mutant alcohol dehydrogenase different from SEQ ID NO:2. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Factors to be considered in determining whether undue experimentation is required are summarized in In re Wands 858 F.2d 731, 8 USPQ2nd 1400 (Fed. Cir. 1988). They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.

The claims are drawn to mutant alcohol dehydrogenase having unlimited structure. The scope of the claims is not commensurate with the enablement provided by the disclosure with regard to the extremely large number of constructs broadly encompassed by the claims. Therefore, the breadth of these claims is much larger than the scope enable by the specification.

The specification, which places weak limitation on the structure of the polypeptides as discussed above, does not support the broad scope of the claims because the specification does not establish: (A) regions of the alcohol dehydrogenase structure which may be modified without effecting dehydrogenase activity while increasing its affinity towards NAD(H); (B) the general tolerance of to modification and extent of such tolerance; (C) a rational and predictable scheme for modifying any

Art Unit: 1652

residues with an expectation of obtaining the desired biological function; and (D) the specification provides insufficient guidance as to which of the essentially infinite possible choices is likely to be successful.

While recombinant and mutagenesis techniques are known, it is not routine in the art to screen a large number of possible combinations .

Therefore, one of ordinary skill would require guidance in order to make mutant alcohol dehydrogenase, having increased affinity towards NAD(H), different from SEQ ID NO:2 in a manner reasonable correlated with the scope of the claims. Without such guidance, the experimentation left to those skilled in the art is undue.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1, with its dependent claims and claims 7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1, line 1, after the phrase "at least one acidic amino acid" the phrase "of the wildtype enzyme" should be inserted to complete

Also in claim 1, line 4, the phrase "an unmodified" is confusing because as written, the affinity between a NAD(H) and modified enzyme is compared to the affinity between a NAD(H) and any unmodified enzyme.

In claim 7, without the recitation of the SEQ ID NO, position "38" is unclear.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in-

(1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effect under this subsection of a national application published under section 122(b) only if the international application designating the United States was published under Article 21(2)(a) of such treaty in the English language; or
(2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that a patent shall not be deemed filed in the United States for the purposes of this subsection based on the filing of an international application filed under the treaty defined in section 351(a).

Claims 1-7 are rejected under 35 U.S.C. 102(e) as being anticipated by Hummel et al.

The mutant *Lactobacillus brevis* dehydrogenase of SEQ ID NO:2 of the instant invention differs from the wildtype dehydrogenase by one residue, an Aspartic acid at position 38 instead of a Glycine. Hummel et al. (U.S. Patent No. 6,413,750) teach a mutant alcohol dehydrogenase from *L. brevis* wherein a Glycine, which corresponds to the residue 38 at position of SEQ ID NO:2 of the instant invention, has been mutated to an Aspartic acid (Column 2 through Column 3 and claim 1). Hummel et al. teach that the mutant dehydrogenase has greater affinity towards NAD(H) (Column 2 and claim 1). Therefore, the teachings of Hummel et al. anticipates claims 1-7.

No claims are allowed.

Art Unit: 1652

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong Pak whose telephone number is 703-308-9363. The examiner can normally be reached on 8:00 A.M. to 4:30 P.M weekdays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 703-308-3804. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Yong Pak
Patent Examiner

November 14, 2002



PONNATHAPU ACHUTAMURTHY
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600